RxDoctor Payments Data

Alex Habibe, MD

Internal Medicine · Fresno, CANPI 1629075395

Payments from drug & device makers

$1,179in general payments, 2019–2025

Across 84 payments — averaging $14.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$561
  • Boehringer Ingelheim$275
  • Novo Nordisk$69
  • Lilly USA, LLC$68
  • Novartis$64
  • AstraZeneca$44
  • plus $97 from 5 others

What the payments were for

  • Food & beverage$1,16799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,179 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$107,536
Medicare patients
238
Services billed
1,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$149,003
Repatha SureclickEvolocumab78$74,555
JardianceEmpagliflozin52$66,588
OzempicSemaglutide40$55,587
TrulicityDulaglutide35$44,730
Humalog Kwikpen U-200Insulin Lispro31$25,028
MyrbetriqMirabegron33$23,461
MounjaroTirzepatide14$18,934
FarxigaDapagliflozin Propanediol13$17,385
JanuviaSitagliptin Phosphate13$14,094
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,004
EdarbiAzilsartan Medoxomil19$10,678
LinzessLinaclotide13$10,541
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,319
SynthroidLevothyroxine Sodium96$9,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Dilantin$561$151,534192 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat$275$80,96282 claims
Lilly USA, LLCTrulicity, Mounjaro$68$63,66449 claims
Novo NordiskOzempic$69$55,58740 claims
AstraZenecaFarxiga, Breztri Aerosphere$44$26,70428 claims
MerckJanuvia$19$14,09413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →